LMAT

Business Context and Reporting Period

Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: LeMaitre Vascular is a global provider of medical devices for the treatment of peripheral vascular disease. The company develops, manufactures, and markets disposable and implantable vascular devices used by vascular surgeons and interventionalists. Its strategy focuses on expanding a direct sales force, acquiring complementary products, and developing in-house manufacturing capabilities. In October 2006, the company completed its Initial Public Offering (IPO).

Key Financial Metrics

Note: The company reported a net loss in 2006 despite revenue growth, primarily due to increased operating expenses and a provision for income taxes.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13% to $34.6 million, driven by a 45% increase in the Endovascular & Dialysis Access category and expansion of the direct sales force.
• Profitability Decline: The company shifted from a net income of $55,000 in 2005 to a net loss of $1.2 million in 2006. Operating expenses increased significantly, particularly Sales and Marketing (up 39%) and General and Administrative (up 11%), reflecting costs associated with becoming a public company and expanding the sales team.
• Liquidity Transformation: Cash and cash equivalents surged from $0.8 million to $15.4 million following the October 2006 IPO, which raised approximately $35.8 million in net proceeds.
• Debt Elimination: The company used $3.9 million of IPO proceeds to pay down all outstanding indebtedness, resulting in zero debt as of December 31, 2006.
• Product Discontinuation: The company ceased production and sales of the Expedial Vascular Access Graft product line due to unfavorable clinical study data, resulting in impairment charges and inventory write-downs.

Guidance, Outlook, and Risks

Management Commentary & Outlook: Management expects to continue investing in the expansion of the direct sales force, clinical studies, and acquisitions. The company does not expect to achieve profitability in the near term due to these substantial expenditures. The company plans to pursue regulatory approvals for its UniFit Abdominal Stent Graft in the U.S. and EndoFit Thoracic Stent Graft in China.

Key Risks and Contingencies:

• Regulatory Approval: Critical products (UniFit and EndoFit) are in clinical studies. Failure to obtain FDA or foreign regulatory approval could materially harm the business.
• Profitability: The company explicitly states it does not expect to be profitable in the near term and may require additional capital.
• Intellectual Property: The company faces opposition proceedings from Boston Scientific Corporation regarding European patents related to its stent grafts.
• Supply Chain: Reliance on single-source suppliers for key components (e.g., nitinol stents) poses a risk of supply disruption.
• Reimbursement: Sales depend on third-party reimbursement policies, which are subject to legislative and regulatory changes.

Investor Verification Checklist

• Clinical Trial Status: Verify the progress and enrollment numbers of the UNITE study (UniFit) and the Chinese clinical study (EndoFit), as these are critical for future revenue growth.
• Regulatory Opposition: Monitor the outcome of the European Patent Office opposition proceedings initiated by Boston Scientific regarding the company's stent graft patents.
• Capital Expenditure Run-rate: Assess the burn rate of the $30.8 million in cash and marketable securities against the stated plan to expand the sales force and fund clinical trials.
• Direct Sales Conversion: Evaluate the success of converting distributor markets to direct sales, which impacts gross margins and cash flow cycles.
• Product Mix Shift: Confirm the continued growth trajectory of the Endovascular & Dialysis Access segment, which drove the majority of revenue growth in 2006.